{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:02:28Z","timestamp":1776542548530,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81973289"],"award-info":[{"award-number":["81973289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemoresistance reduces the 5-year survival rate of endometrial cancer patient, which is the current major obstacle for cancer therapy. Increasing evidence state that Nrf2 contributes to chemoresistance in several kinds of cancer. However, its role in endometrial cancer cells remains unclarified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemistry staining was used to detect the expression of Nrf2 in normal patient and endometrial cancer patient. Stable transfection Ishikawa cell line with high level of Nrf2 was established to evaluate its role in chemoresistance. Dot blot assays were used to assess global hydroxymethylation level after stigmasterol treatment. Cellular growth profile was detected by CCK8 assay. Western blot was used to evaluate the changes of the target molecules after various treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nrf2 is overexpressed in endometrial cancer tissues compared with the normal endometrium. Overexpression of Nrf2 resulted in decrease sensitivity to cisplatin. In addition, stigmasterol has been identified as a novel Nrf2 inhibitor. It enhanced the sensitivity of endometrial cancer cells to cisplatin, and the underlying mechanism is that stigmasterol declines the Nrf2 protein level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identified stigmasterol as a new potential inhibitor of Nrf2 and highlight a critical role of stigmasterol in overcoming chemoresistance in endometrial cancer therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-020-01470-x","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T16:02:52Z","timestamp":1602000172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway"],"prefix":"10.1186","volume":"20","author":[{"given":"Hong","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-4890","authenticated-orcid":false,"given":"Mingzhu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"2","key":"1470_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0304-3835(92)90180-4","volume":"62","author":"PG Satyaswaroop","year":"1992","unstructured":"Satyaswaroop PG, Clarke CL, Zaino RJ, Mortel R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett. 1992;62(2):107\u201314.","journal-title":"Cancer Lett"},{"issue":"2","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/gyno.1998.5322","volume":"73","author":"T Perez-Medina","year":"1999","unstructured":"Perez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol. 1999;73(2):299\u2013304.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1470_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/ijgc-00009577-200409000-00028","volume":"14","author":"A Ben-Arie","year":"2004","unstructured":"Ben-Arie A, Perlman S, Hazan Y, Solomon LA, Edwards C, Kaplan AL. High-risk endometrial cancer in young indigent women. Int J Gynecol Cancer. 2004;14(5):927\u201330.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1470_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ygyno.2009.08.011","volume":"115","author":"O Zivanovic","year":"2009","unstructured":"Zivanovic O, Carter J, Kauff ND, Barakat RR. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol. 2009;115(3):504\u20139.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1677\/ERC-08-0266","volume":"16","author":"P Chaudhry","year":"2009","unstructured":"Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer. 2009;16(2):363\u201380.","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1128\/MCB.24.16.7130-7139.2004","volume":"24","author":"A Kobayashi","year":"2004","unstructured":"Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004;24(16):7130\u20139.","journal-title":"Mol Cell Biol"},{"issue":"1\u20132","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2007.10.022","volume":"260","author":"JM Cho","year":"2008","unstructured":"Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008;260(1\u20132):96\u2013108.","journal-title":"Cancer Lett"},{"issue":"4","key":"1470_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","volume":"135","author":"T Shibata","year":"2008","unstructured":"Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 2008;135(4):1358\u201368.","journal-title":"Gastroenterology"},{"issue":"10","key":"1470_CR10","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-08-2822","volume":"15","author":"S Homma","year":"2009","unstructured":"Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009;15(10):3423\u201332.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/carcin\/bgn095","volume":"29","author":"XJ Wang","year":"2008","unstructured":"Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29(6):1235\u201343.","journal-title":"Carcinogenesis"},{"issue":"19","key":"1470_CR12","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1158\/0008-5472.CAN-08-1401","volume":"68","author":"A Singh","year":"2008","unstructured":"Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008;68(19):7975\u201384.","journal-title":"Cancer Res"},{"issue":"11","key":"1470_CR13","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 2016;11(11):3214\u201325.","journal-title":"ACS Chem Biol"},{"issue":"49","key":"1470_CR14","doi-asserted-by":"publisher","first-page":"19589","DOI":"10.1073\/pnas.0709483104","volume":"104","author":"XJ Wang","year":"2007","unstructured":"Wang XJ, Hayes JD, Henderson CJ, Wolf CR. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA. 2007;104(49):19589\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1470_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.freeradbiomed.2014.03.009","volume":"71","author":"J Xu","year":"2014","unstructured":"Xu J, Wang H, Ding K, Zhang L, Wang C, Li T, et al. Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE pathway. Free Radic Biol Med. 2014;71:186\u201395.","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"1470_CR16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/mc.21921","volume":"52","author":"Y Zhong","year":"2013","unstructured":"Zhong Y, Zhang F, Sun Z, Zhou W, Li ZY, You QD, et al. Drug resistance associates with activation of Nrf2 in MCF-7\/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol Carcinog. 2013;52(10):824\u201334.","journal-title":"Mol Carcinog"},{"key":"1470_CR17","first-page":"6181754","volume":"2019","author":"X Zhou","year":"2019","unstructured":"Zhou X, Wang W, Wang C, Zheng C, Xu X, Ni X, et al. DPP4 Inhibitor Attenuates Severe Acute Pancreatitis-Associated Intestinal Inflammation via Nrf2 Signaling. Oxid Med Cell Longev. 2019;2019:6181754.","journal-title":"Oxid Med Cell Longev"},{"issue":"20","key":"1470_CR18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1101\/gad.225680.113","volume":"27","author":"MC Jaramillo","year":"2013","unstructured":"Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27(20):2179\u201391.","journal-title":"Genes Dev"},{"issue":"13","key":"1470_CR19","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1158\/0008-5472.CAN-10-0713","volume":"70","author":"T Jiang","year":"2010","unstructured":"Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010;70(13):5486\u201396.","journal-title":"Cancer Res"},{"key":"1470_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ebiom.2018.12.044","volume":"40","author":"H Lu","year":"2019","unstructured":"Lu H, Ju DD, Yang GD, Zhu LY, Yang XM, Li J, et al. Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma. EBioMedicine. 2019;40:276\u201389.","journal-title":"EBioMedicine"},{"issue":"4","key":"1470_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1073\/pnas.1014275108","volume":"108","author":"D Ren","year":"2011","unstructured":"Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci USA. 2011;108(4):1433\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"42","key":"1470_CR22","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1038\/s41388-018-0360-7","volume":"37","author":"M Bai","year":"2018","unstructured":"Bai M, Yang L, Liao H, Liang X, Xie B, Xiong J, et al. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism. Oncogene. 2018;37(42):5666\u201381.","journal-title":"Oncogene"},{"issue":"2","key":"1470_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3892\/ijo.2017.4042","volume":"51","author":"D Tian","year":"2017","unstructured":"Tian D, Shi Y, Chen D, Liu Q, Fan F. The Wnt inhibitor LGK-974 enhances radiosensitivity of HepG2 cells by modulating Nrf2 signaling. Int J Oncol. 2017;51(2):545\u201354.","journal-title":"Int J Oncol"},{"issue":"1","key":"1470_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/toxins6010371","volume":"6","author":"A Limonciel","year":"2014","unstructured":"Limonciel A, Jennings P. A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity. Toxins (Basel). 2014;6(1):371\u20139.","journal-title":"Toxins (Basel)"},{"issue":"11","key":"1470_CR25","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.freeradbiomed.2011.03.008","volume":"50","author":"X Tang","year":"2011","unstructured":"Tang X, Wang H, Fan L, Wu X, Xin A, Ren H, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2\/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011;50(11):1599\u2013609.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1158\/1078-0432.CCR-13-2311","volume":"20","author":"C Huang","year":"2014","unstructured":"Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin Cancer Res. 2014;20(6):1477\u201388.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1470_CR27","first-page":"1502","volume":"7","author":"LJ Bao","year":"2014","unstructured":"Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX, Yao M, Zhang DD, et al. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol. 2014;7(4):1502\u201313.","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"1470_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1593\/neo.11750","volume":"13","author":"T Shibata","year":"2011","unstructured":"Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia. 2011;13(9):864\u201373.","journal-title":"Neoplasia"},{"issue":"9","key":"1470_CR29","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1084\/jem.20170438","volume":"214","author":"C Saygin","year":"2017","unstructured":"Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med. 2017;214(9):2715\u201332.","journal-title":"J Exp Med"},{"issue":"3","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/15548627.2016.1271512","volume":"13","author":"N Eritja","year":"2017","unstructured":"Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017;13(3):608\u201324.","journal-title":"Autophagy"},{"issue":"55","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"93502","DOI":"10.18632\/oncotarget.19548","volume":"8","author":"J Wu","year":"2017","unstructured":"Wu J, Bao L, Zhang Z, Yi X. Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells. Oncotarget. 2017;8(55):93502\u201315.","journal-title":"Oncotarget"},{"key":"1470_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/biom9100550","volume":"9","author":"JH Lee","year":"2019","unstructured":"Lee JH, Rangappa S, Mohan CD, Sethi G, Lin ZX, et al. Brusatol a Nrf2 inhibitor targets STAT3 signaling cascade in head and neck squamous cell carcinoma. Biomolecules. 2019;9:550.","journal-title":"Biomolecules."},{"key":"1470_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2014.11.003","volume":"78","author":"A Olayanju","year":"2015","unstructured":"Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015;78:202\u201312.","journal-title":"Free Radic Biol Med"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-020-01470-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T03:21:15Z","timestamp":1633490475000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-020-01470-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1186\/s12935-020-01470-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-24076\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-24076\/v2","asserted-by":"object"}]},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human samples were obtained under approval of the institutional review board from the Medical College, Tongji University, China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Individual\u2019s personal data details from donors are not mentioned in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}